Novel use of burosumab in refractory iron-induced FGF23-mediated hypophosphataemic osteomalacia

Rheumatology (United Kingdom)

Volumn 59, Issue 8, 2020, Pages 2166-2168

  Amarnani, Raj ^a   Travis, Simon ^b   Javaid, Muhammad Kassim ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALFACALCIDOL; ALKALINE PHOSPHATASE; BUROSUMAB; FERRIC CARBOXYMALTOSE; FIBROBLAST GROWTH FACTOR 23; IRON; PHOSPHATE; FERRIC ION; FIBROBLAST GROWTH FACTOR; MALTOSE; MONOCLONAL ANTIBODY;

ADULT; ALKALINE PHOSPHATASE LEVEL; CASE REPORT; CLINICAL ARTICLE; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CROHN DISEASE; DIARRHEA; DRUG SUBSTITUTION; FEMORAL HEAD FRACTURE; FEMUR FRACTURE; FOLLOW UP; FOOT PAIN; FRACTURE; FRACTURE HEALING; GASTROINTESTINAL DISEASE; HIP ARTHROPLASTY; HIP PAIN; HUMAN; HYPOPHOSPHATEMIA; HYPOPHOSPHATEMIC RICKETS; INTESTINAL BLEEDING; IRON DEFICIENCY ANEMIA; LEG PAIN; LETTER; MALE; METATARSAL BONE; NUCLEAR MAGNETIC RESONANCE IMAGING; PELVIS FRACTURE; PHOSPHATE BLOOD LEVEL; PORTAL HYPERTENSION; PRIORITY JOURNAL; SUPPLEMENTATION; TARSAL BONE; BLOOD; OSTEOMALACIA; TREATMENT OUTCOME;

ADULT; ANEMIA, IRON-DEFICIENCY; ANTIBODIES, MONOCLONAL, HUMANIZED; FERRIC COMPOUNDS; FIBROBLAST GROWTH FACTORS; HUMANS; HYPOPHOSPHATEMIA; MALE; MALTOSE; OSTEOMALACIA; TREATMENT OUTCOME;

EID: 85088680573     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kez627     Document Type: Letter

References (7)

1. Schouten BJ, Doogue MP, Soule SG, Hunt PJ. Iron polymaltose-induced FGF23 elevation complicated by hypophosphataemic osteomalacia. Ann Clin Biochem 2009;46:167-9.
2. Yamamoto S, Okada Y, Mori H, Fukumoto S, Tanaka Y. Fibroblast growth factor 23-related osteomalacia caused by the prolonged administration of saccharated ferric oxide. Intern Med 2012;51:2375-8.
3. Shimizu Y, Tada Y, Yamauchi M et al. Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia. Bone 2009;45:814-6.
4. Klein K, Asaad S, Econs M, Rubin JE. Severe FGF23- based hypophosphataemic osteomalacia due to ferric carboxymaltose administration. BMJ Case Rep 2018;2018:bcr-2017-222851.
5. Hanudel MR, Laster M, Salusky IB. Non-renal-related mechanisms of FGF23 pathophysiology. Curr Osteoporos Rep 2018;16:724-9.
6. Wolf M, Chertow GM, Macdougall IC et al. Randomized trial of intravenous iron-induced hypophosphatemia. JCI Insight 2018;3:124486.
7. Insogna KL, Briot K, Imel EA et al. A randomized, doubleblind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with x-linked hypophosphatemia: week 24 primary analysis. J Bone Miner Res 2018;33:1383-93.